Moderna set to file for us, EU clearance for its coronavirus vaccine. According to today’s article on ForexLive, “Moderna reaffirms that its vaccine is 94.1% effective in primary analysis
– Vaccine was 94.1% effective in analysis of Phase 3 study, after 196 virus cases
– Vaccine was 100% effective against strict virus cases in trial
Another Monday, another dose of vaccine optimism to hit the market.”

Moderna to ask FDA to authorize vaccine. According to today’s article on The Wall Street Journal, “Moderna will ask U.S”

According to today’s article on Bloomberg Quint, “Moderna Plans to Seek U.S., EU Clearance for Covid Vaccine.”

Moderna to file EUA for coronavirus vaccine candidate, which previewed 94.1% efficacy. According to today’s article on MarketWatch, “Moderna Inc”

According to today’s article on MarketWatch, “Moderna shares soar 11% on filing for emergency-use authorization for vaccine.”

Stocks making the biggest moves premarket: Moderna, IHS markit, slack & more. According to today’s article on CNBC, “Some of the stocks posting the largest moves before the bell include Moderna, IHS Markit, Slack, and more..”

Stocks making the biggest moves premarket: Moderna, IHS markit, slack & more. According to today’s article on CNBC, “Some of the stocks posting the largest moves before the bell include Moderna, IHS Markit, Slack, and more..”

Stocks making the biggest moves midday: Moderna, IHS markit, nikola, Carnival & more. According to today’s article on CNBC, “Moderna shares rereport on strong efficacy data.”

Shares of Moderna rose by a staggering 16.11% to $147.50 at 14:08 EST on Monday, after two successive sessions in a row of gains. The Nasdaq Stock Market is dropping 0.37% to $12,161.20, after four sequential sessions in a row of gains, on what up to now seems, a somewhat negative trend trading session today.

Moderna’s last close was $127.03, 2.37% below its 52-week high of $151.00.

Moderna’s sales growth is 1425.2% for the current quarter and 9666.5% for the next. The company’s growth estimates for the current quarter is a negative 48.6% and positive 437.1% for the next.

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna’s stock is valued at $147.50 at 14:08 EST, under its 52-week high of $151.00 and way higher than its 52-week low of $17.68.

Moderna’s worth is way above its 50-day moving average of $80.78 and way above its 200-day moving average of $70.99.

LEAVE A REPLY

Please enter your comment!
Please enter your name here